Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.
Roy S HerbstYi-Long WuThomas JohnChristian GroheMargarita MajemJie WangTerufumi KatoJonathan Wade GoldmanKonstantin LaktionovSang-We KimChong-Jen YuHuu Vinh VuShun LuKye Young LeeGuzel MukhametshinaCharuwan AkewanlopFilippo de MarinisLaura BonannoManuel DómineFrances A ShepherdDamien UrbanXiangning HuangAna BolanosMarta StachowiakMasahiro TsuboiPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
These updated data demonstrate prolonged DFS benefit over placebo, reduced risk of local and distant recurrence, improved CNS DFS, and a consistent safety profile, supporting the efficacy of adjuvant osimertinib in resected EGFR-mutated NSCLC.
Keyphrases
- phase iii
- small cell lung cancer
- epidermal growth factor receptor
- lymph node
- open label
- advanced non small cell lung cancer
- double blind
- early stage
- clinical trial
- placebo controlled
- phase ii
- brain metastases
- tyrosine kinase
- prognostic factors
- electronic health record
- blood brain barrier
- wild type
- big data
- free survival
- randomized controlled trial
- machine learning
- artificial intelligence
- data analysis